Contemporary Taiwan finds itself navigating unprecedented healthcare challenges, having transitioned into a super-aged society with unexpected speed, compounded by one of the lowest birth rates globally. In 2024, to secure the nation’s future, President Lai Ching-te launched his flagship ‘Healthy Taiwan’ initiative. This comprehensive blueprint strives to shift the public healthcare apparatus from a model of reactive treatment to one focused on preventative care, wellness, and structural sustainability.
The urgency behind the programme stems from severe population pressures that strain Taiwan’s National Health Insurance (NHI) framework. “Taiwan has become an extremely elderly society at a pace without regional precedent – Japan took 14 years to cross that threshold whereas Taiwan took merely seven,” notes Tina Graves, General Manager at GSK. “Moreover, this is occurring in tandem with a birth rate that has fallen to among the lowest recorded anywhere on the planet,” she adds.
Such a rapid shift has fundamentally altered the dynamics of healthcare delivery, escalating both the volume and complexity of daily medical cases. Chen Chien-jen, ex-minister of health and welfare, former vice president, and incoming president of Academia Sinica explains: “Population ageing can now be considered the defining challenge of our time. Our combination of both exceptionally low fertility rates and extended lifespans means approximately 20 percent of our population is now in the grey zone, creating twin pressures of ever greater healthcare complexity and an escalating burden of long-term care demands.”
What’s more, the financial imbalance of this demographic change threatens the foundations of the entire national health apparatus. “The long-term sustainability challenges of such a situation are profound and require urgent, out-of-the-box solutions to combat the ensuing distortionary effect on the nation’s health system,” warns Vincent Tong, Managing Director at MSD. Indeed, he highlights the stark fiscal reality: “With a population comparable to Scandinavia, Taiwan now counts 4.7 million citizens over 65, with less than 18 percent of the population consuming more than 42 percent of the overall healthcare expenditure envelope.”
Fortunately, because President Lai brings a background as a physician to the state’s highest office, health policy has already been elevated from a standard public service department budget item to a core pillar of national security and identity. “For the first time in our history leading Taiwan toward becoming a healthier nation constitutes a fundamental governmental objective,” enthuses Minister of Health and Welfare Chung-Liang Shih, pointing out that the new initiative mobilises the full machinery of government behind ambitious goals like reducing cancer mortality by one-third by 2030, and curbing ‘the three highs’ of elevated blood glucose, blood pressure, and cholesterol to counteract obesity.
“What we’re witnessing is far more than just policy nomenclature, but rather a first-of-a-kind, overarching and comprehensive strategic vision for transitioning our nation out of ‘sick-care’ and into ‘health-care’, reflecting a deep-seated presidential commitment to future population health excellence,” he proudly affirms.
Financing a New Era of Wellness
Underpinning such heady ambitions has been a concerted effort to increase healthcare expenditure. “Crucially we’ve witnessed the Healthy Taiwan initiative being supported not only by aspirational statements, but also by tangible monetary commitments and substantive policy reforms, with increased healthcare system budget allocations buttressing this vision financially,” observes Vivian Kuo, general manager for Taiwan & Hong Kong at the Belgian biopharma, UCB.
This is imperative in the eyes of many industry insiders who point out that Taiwan has traditionally been less generous than many of its peer economies when it comes to financing next-generation medicines and a modern and forward-looking healthcare setup that is fit-for-the-future. “Taiwan’s GDP is nowadays broadly comparable with countries like Japan and Spain, and yet public expenditure on areas like innovative therapies has consistently been lower, explains Hans Duijf, general manager at the Danish speciality player, Novo Nordisk. “The money has long been there, but whether the commensurate political willpower existed to definitively move the needle with regards to healthcare transformation has often been called into question,” he recalls.
Yet this time certainly looks different. “We have substantially expanded the overall envelope allocated to public health. Over three decades, annual growth averaged three to four percent yet this was increased in 2025 to between six and 6.5 percent, reframing the global budget as a healthcare investment rather than a cost-containment instrument, and enabling broader coverage of novel therapies alongside improved provider reimbursement,” confirms Minister Chung-Liang Shih.
Moreover, an impressive NTD 48.9 billion (USD 1.56 billion) ‘Cultivation Programme’ fund has been set up to finance health-related infrastructure and workforce improvements and to advance the public health system’s digital capabilities. “Whereas the global budget growth rate of 6.5 percent applies specifically to healthcare service delivery and pharmaceutical expenditure – operational costs, essentially the Cultivation Programme, receive separate, supplementary budgetary allocations ringfenced for infrastructural, workforce-related, and digital transformations. This dual-funding approach ensures neither operational necessities nor strategic investments receive inadequate resources,” details Shih.
“It ultimately boils down to a question of spending wisely. On the one hand, Taiwan is proud of it track record of being able to achieve more with less, and we shall continue to remain faithful to our commitment of delivering a high-quality, low-cost health system,” affirms Lian-Yu Chen, director general of the National Health Insurance Administration. She notes that the NHI enjoys the distinction of being one of the most successful universal health coverage models in the world and that all this has been achieved this while maintaining relatively modest expenditure levels, which at 7.5 percent of GDP ranks far below OECD averages.
“At the same time, we recognise that health expenditure is not a cost but an investment in the future wellbeing and productivity of the nation so are ready to spend big in areas of maximal impact where the evidence shows extra spending can make a real positive difference,” Chen continues, referencing the recent establishment of a dedicated NTD 10 billion (USD 310 million) Cancer Drug Fund.
“Frankly, the enactment of a special funding mechanism for oncology treatments is a real statement of intent which has meaningfully improved access to breakthrough cancer medicines. We view this as a genuine opportunity to explore something similar in the context of serious chronic diseases and are very optimistic about the prevailing direction of progress,” acknowledges Duijf.
Parallel Policy Reform
Meanwhile, the newfound financial firepower is being backed up by significant policy reform.
First, Taiwan’s policymakers established the National Health Technology Assessment Centre, modelled explicitly on the United Kingdom’s National Institute for Health and Care Excellence in a bid to rationalise reimbursement decisions and ensure that the most promising and impactful therapies can receive public funding.
“Following an extensive study visit to NICE two years ago, it became clear that objective reimbursement decisions require an assessment body structurally independent from the payer. Our HTA Centre, now being established, will operate separately from the National Health Insurance Administration, replacing the previous embedded working-group model within the Centre for Drug Evaluation and ensuring rigorous, evidence-based decision-making,” promises Shih.
Secondly, the government has introduced parallel review pathways for breakthrough medicines materially shortening time taken for patients to access game changing treatments. “Historically, innovative therapies faced sequential regulatory and reimbursement reviews, often delaying patient access by two to three years after FDA approval. Under a new framework effective from last year, manufacturers can now submit for regulatory approval and National Health Insurance reimbursement concurrently which has shown to substantially abbreviate review timelines and expedite new therapy approvals,” applauds UCB’s Vivian Kuo.
The real-world impact of this reforming spirit extends beyond procedural change. UCB recently secured a historic regulatory decision — the lifting of a 45-year prohibition on fenfluramine, previously restricted due to its chemical similarity to amphetamine — enabling access for patients with Dravet syndrome and Lennox-Gastaut syndrome, two severe treatment-refractory epilepsies. “Had we simply accepted the status quo, registration and importation would have remained impossible,” reflects Kuo. “We recognised the imperative to challenge this paradigm — engaging government authorities, medical societies, and patient advocacy organisations collectively until the government rendered its decision.”
A similar dynamic is playing out in neurology. Following TFDA approval of lecanemab earlier in 2025 — the first disease-modifying therapy for early Alzheimer’s disease, targeting amyloid protein aggregation rather than symptoms alone — Eisai worked with neurologists, radiology centres, and hospital teams to build an entirely new clinical pathway around it. “Before treatment can begin, physicians must confirm amyloid pathology, and ongoing MRI monitoring is recommended to manage safety risks,” explains Hu. “Preparing the market meant ensuring diagnostic, monitoring, and follow-up processes were consistently understood across the ecosystem.” For a healthcare system serving a rapidly ageing population, the ability to absorb and operationalise therapies of this complexity is itself a measure of maturity.
Such joined up processes are actually emblematic of a new streamlined and holistic way of operating. “Traditionally, the Taiwan FDA, acting as regulatory affairs authority, and the NHIA, serving as the reimbursement authority, operated as separate domains. Increasingly, however, we see them collaborating meaningfully and in a coordinated manner,” perceives MSD’s Vincent Tong. “Having worked across multiple markets, I find this modus operandi genuinely impressive and rather uncommon.”
TFDA Director General Chih-Kang Chiang agrees that there is a concerted effort to have all parts of the institutional landscape pulling together, proclaiming that, “under the auspices of Healthy Taiwan, “Innovation must be matched by implementation.”
“We regard the TFDA as playing a central role in this process by ensuring scientific integrity while simultaneously working to introduce the necessary regulatory flexibility to help innovative products reach patients faster,” he confirms.
A further important shift has been the authorities’ inclusive posture towards industry. “The tone of our conversations is nowadays collaborative rather than adversarial, which I think reflects well on the authorities here. There is a genuine openness to dialogue,” says Duijf.
Grant Hu, CEO of Eisai’s Taiwanese affiliate and president of the International Research-Based Pharmaceutical Manufacturers Association (IRPMA) agrees. “Taiwan now provides an environment where scientific evidence and clinical value are recognised, enabling us to demonstrate meaningful outcomes rather than engaging solely in price discussions,” he posits, adding that “by staying closely aligned with clinical realities and supporting evidence-based decision-making, Eisai strives to be a constructive partner within Taiwan’s oncology ecosystem, contributing both practically and sustainably to a better future.”
Pivoting From ‘Sick-care’ to ‘Healthcare’
Perhaps the most enlightened aspect of Taiwan’s new approach to national healthiness has been a shift in philosophy from ‘disease-focused care’ to ‘comprehensive health management’ premised upon sustaining wellness. “We’ve developed what we call the P4 Framework which requires reconceptualising healthcare as a continuum rather than episodic intervention, by focusing on energies upon preventive, predictive, personalised, and participatory medicine,” reveals Chen Chien-jen. “This entails stopping disease occurrence in the first place and inhibiting its progression at the very earliest instance, by leveraging individually-targeted precision therapies, predictive analytics and co-opting patients in their own health management,” he elaborates.
Most industry insiders welcome this paradigm shift and how it presupposes pharmaceutical developers transcending their conventional role as purveyors of drugs to become true partners in eliciting enduring positive health outcomes. “What I find genuinely exciting and motivating about the moment we are in is that our future innovations will be positioned not merely to treat people who are already ill, but to help people remain healthy for longer. That entails a meaningful shift in the role of biopharma: from addressing a defined group of diagnosed patients to contributing to the health of the broader population, enthuses Duijf.
Realising such an approach has necessitated the Taiwanese public health system investing much more prolifically in diagnostics and early-stage screening than would hitherto have been the case. “The strategy being pursued is essentially to try and transition expenditure away from end-stage expensive therapeutics and more towards early intervention paradigms by reinforcing detection infrastructure and unlocking multi-omics capabilities with a view to nipping diseases in the bud and prolonging wellness,” reasons Jerry Cheng, general manager in Taiwan, Hong Kong, and Macau for Illumina, a California-based genomics and sequencing speciality outfit.
For instance, according to John Chang, CEO of the Formosa Cancer Foundation, nationwide screening capacity against cancer has ramped up considerably. “Around 4.8 million people were screened annually in 2023 and 2024, but in 2025 cumulative screening numbers had surpassed 5.87 million – an increase of more than 25 percent year on year,” he exclaims.
Meanwhile, Taichung Veterans General Hospital (TVGH), the largest national medical centre in Taiwan, operating 1,632 beds and serving 10,000 outpatients daily, has achieved international renown for its advanced use of third-generation sequencing screening. “For infectious disease diagnostics, we employ 3G sequencing technology capable of detecting more than 20,000 pathogens – including 10,000 bacterial species, as well as thousands of viruses, fungi, and parasites – within hours. This allows physicians to select antibiotics with far greater precision yielding substantial health benefits,” confirms the hospital’s superintendent, Professor Yun-Ching Fu.
Moreover, the island has been managing to harness its largely unprecedented level of digital maturity and unique data infrastructure to attain tangible leaps forward in advancing personalised, precision medicine. “Taiwan offers a rare combination of scale, structure, and capability that supports healthcare innovation in a very practical way. With a population of around 23 million concentrated on a single island, it benefits from a dense concentration of clinical talent underpinned by a strong technology base,” believes Professor Der-Yang Cho superintendent at China Medical University Hospital (CMUH).
“The critical enabler is the National Health Insurance system, which provides near-universal coverage and creates a highly standardised healthcare environment. This level of coverage allows large-scale, data-driven innovation to take place, in a manner and pace that would otherwise be practically unthinkable,” he argues.
“Taiwan also possesses additional advantages in this domain owing to its robust AI chip industry, as artificial intelligence is essential for analysing the extensive databases generated from individual omics data, as well as the big data derived from universal healthcare,” affirms Chi-Huey Wong, president of the Institute for Biotechnology and Medicine Industry (IBMI) and Scripps Family Chair Professor at the Scripps Research Institute in San Diego, pointing to the ongoing success of programmes such the Taiwan Precision Medicine Initiative which has so far managed to collect genetic and clinical data from over half a million participants to enable detailed analysis of personalised data.
“Looking ahead, you could even say that data governance represents our most powerful strategic asset. Around 80 percent of chronic disease patients – equating to over 8.5 million citizens out of our 23.5 million strong population – are now enrolled in digitally enabled care networks through the ‘Big Family Physician Platform,’ enabling detailed analysis of utilisation, comorbidities, and costs,” confides the NHI’s Lian-Yu Chen.
“We are simultaneously in the process of linking National Health Insurance and long-term care datasets – previously siloed systems – through a multi-year integration launched this June which will enable full lifespan analysis, from chronic disease through acute events to long-term care, supporting not only better health outcomes, but more coherent and cost-effective policy design as well,” she adds.
Reinventing Care Delivery Models
With all these factors converging, it is little wonder Taiwan is nowadays considered to be positioned at the forefront of redefining care delivery models. “As next-generation healthcare increasingly moves beyond the hospital, Taiwan is ready and primed to advance telemedicine and remote-monitoring models, particularly for chronic disease management,” insists Der-Yang Cho, noting that the CMUH is already deploying concrete solutions such as home haemodialysis monitoring systems that integrate device data and vital signs with early-warning alerts to support patient safety outside the hospital setting.
“Remotely delivered healthcare like home dialysis expands capacity by shifting care to patients’ homes, reducing the dependence on in-centre resources, but only scales sustainably when it is properly supported by digital monitoring, integrated logistics, and consistent clinical support,” warns Gary Wong, cluster general manager at the American-headquartered healthcare solutions provider Vantive. Yet he believes that Taiwan has reached a stage where it can credibly provide that style of full enabling ecosystem and thus unlock a whole host of important benefits including a reduction in unnecessary hospital visits, cost-efficiencies, and the freeing up of clinicians’ time to redeploy towards areas where they are most needed.
Concurrently, the Taiwanese State has been pushing the concept of Long-Term Care 2.0 which favours community day-care centres and home-based support over nursing homes. “For elderly care, we deliberately rejected the institutionalisation model. We do not want rows of nursing homes. Instead, we have established over 10,000 community day-care centres – think of them as kindergartens for seniors, if you will – offering a much more cost-effective, rationalised, and crucially patient-centric form of solution which integrates healthcare with what I call life-care. In essence, recognising that quality of life matters just as much as medical intervention,” explains Chen Chien-jen.
Rewiring incentive structures
It is not just policies, processes and physical infrastructure that have been undergoing radical reform, but also incentive structures. “Taiwan’s payment system has traditionally relied on fee-for-service models, which resoundingly failed to optimise clinical outcomes,” concedes NHI’s Lian-Yu Chen. “Consequently, we have reverted to pay-for-performance programmes so that physicians managing chronic conditions such as diabetes, hypertension, kidney disease now receive enhanced reimbursement whenever their patients actually improve rather than pegged to the volume of interventions undertaken,” she recounts.
“So far, outcomes for enrolled patients have proved consistently superior, with almost 75 percent of participants achieving improved HbA1c levels within one year, thus validating the model,” Chen claims proudly.
It is perhaps in the area of participatory healthcare that most eyebrows have been raised, however, with the incumbent government pulling out all the stops to try and nudge healthier behaviours on the part of the national population.
“The recent introduction of our ‘Health Coins’ system creates an ecosystem in which behaviours such as regular physical activity, adherence to vaccination schedules, and participation in cancer screening programmes generate redeemable points,” explains Minister Shih, noting that these points can then be exchanged for health-promoting goods and services, including access to fitness facilities and healthier food and beverage options.
“The objective is to establish a self-reinforcing environment in which healthy choices are both rewarded and normalised,” he affirms.
The approach follows in the footsteps of lessons from tobacco control, where Taiwan achieved substantial success by reducing smoking prevalence from 20 percent to 12 percent through a mix of health taxes, bans, and sustained education campaigns which demonstrated that coordinated policy intervention can reshape social norms and behaviour at scale.
“Our preference in promoting wellness, however, has been to begin with softer, behavioural approaches, often described as nudging, delivered through education, social media, school-based programmes, and underpinned with strong incentives, because it is our belief that methods, though gradual, encourage the most durable and thus effective forms of behavioural change,” elaborates Shih.
Health as an Export?
To what extent, then, can Taiwan be regarded as a showcase example for other economies to emulate? “We believe that Taiwan constitutes a perfect living-lab and innovation hub for how to sustainably manage a super-ageing society,” believes IBMI’s Chi-Huey Wong. “Our unique circumstances and very particular set of strengths and capabilities are already attracting substantial investment interest,” he posits.
“I see great scope for the Island to test out, apply and export novel approaches,” agrees Alexis Lin, general manager at the Japanese speciality biopharma Takeda. “Policymakers here have shown unprecedented openness to experimenting with new models. This willingness to pilot ideas is distinctive and renders this market a real paragon internationally when it comes to defining the optimal healthcare strategies of the future,” she concludes.
